Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 21pomalidomide 18Lenalidomide 18Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8Carboplatin 8obinutuzumab 7cemiplimab 7Drug Therapy 7Bevacizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × EPOCH protocol × 1 year × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡